Drug Profile
Research programme: anticancer therapeutics - Sequoia Sciences
Alternative Names: Anticancer compounds - Sequoia SciencesLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sequoia Sciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Sep 2023 Preclinical development in Cancer is ongoing in USA (unspecified route) (Sequoia Sciences pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 11 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)